Investor
Euclidean Capital LLC
CIK 0001825034 · filed 2026-05-15 · SEC filing
13F book
$392.3M
Positions
10
0 new · 2 sold
Largest name
62.1%
Vanguard Intl Equity Index F
Est. mark
$9.41M
Price effect on 10 names still held. Flow $13.4M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Vanguard Intl Equity Index F | — | 3.24M | $243.6M | 62.1% | $4.6M | Added$23.6M |
| Vanguard Index Fds | — | 520K | $102M | 26.0% | $2.71M | Held |
| Ishares Tr | — | 369.6K | $17.3M | 4.4% | −$2.66M | Held |
| Oric Pharmaceuticals, Inc. | ORIC | 989.4K | $12.5M | 3.2% | $4.44M | Held |
| Foghorn Therapeutics Inc. | FHTX | 1.57M | $7.52M | 1.9% | −$975.7K | Held |
| PMV Pharmaceuticals, Inc. | PMVP | 2.63M | $3.26M | 0.8% | −$26.3K | Held |
| Alector, Inc. | ALEC | 1.31M | $2.81M | 0.7% | $771.6K | Held |
| Surrozen Inc | — | 87.7K | $2.55M | 0.7% | $572.7K | Held |
| Tenaya Therapeutics, Inc. | TNYA | 1.02M | $703.3K | 0.2% | −$19.4K | Held |
| Surrozen Inc | — | 170.8K | $2.73K | 0.0% | −$684 | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.